Ars Pharmaceuticals (SPRY): 10% owner sold ~$708K
Flynn James E, 10% owner at Ars Pharmaceuticals, sold ~$708K of Ars Pharmaceuticals shares.
- ~$708K
- Approx. value · 41K sh @ $17.45
- 5.5M
- Holds after · shares reported
- Traded
- Nov 11, 2024
- Filed
- Nov 14, 2024
What stands out in this filing
- After this sale the filing reports 5,498,367 shares, held indirectly.
- 40,596 shares at an average of $17.45 each, as reported on the form.
- No footnote on the form refers to a pre-arranged trading plan (Rule 10b5-1).
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Oct 8, 2024Insider · 2 peopleInsiders: 4 sales (~$2.8M)
- Oct 15, 2024Insider · 2 peopleInsiders: 6 sales (~$3.0M)
- Oct 16, 2024InsiderCFO sold ~$200K of SPRY shares in the open market
- Nov 11, 2024 · this disclosureInsider10% owner sold ~$708K of SPRY shares in the open market
What came next
- Nov 11, 2024Insider · 1 personInsiders: 3 sales (~$8.8M)
- Nov 12, 2024Insider · 3 peopleInsiders: 12 sales (~$4.0M)
- Nov 19, 2024Insider · 2 peopleInsiders: 4 sales (~$2.8M)
- Nov 25, 2024InsiderOfficer sold ~$459K of SPRY shares in the open market
- Nov 26, 2024InsiderOfficer sold ~$593K of SPRY shares in the open market
- Nov 27, 2024InsiderOfficer sold ~$360K of SPRY shares in the open market
- Dec 2, 2024Insider · 3 peopleInsiders: 4 sales (~$2.0M)
- Dec 3, 2024Insider · 2 peopleInsiders: 2 sales (~$1.8M)
- Dec 4, 2024Insider · 3 peopleInsiders: 3 sales (~$919K)
- Dec 5, 2024InsiderOfficer sold ~$702K of SPRY shares in the open market
- Dec 6, 2024InsiderOfficer sold ~$712K of SPRY shares in the open market
- Dec 10, 2024Insider · 3 peopleInsiders: 5 sales (~$3.3M)
- Dec 11, 2024InsiderOfficer sold ~$186K of SPRY shares in the open market
- Dec 12, 2024Insider · 2 peopleInsiders: 2 sales (~$1.7M)
- Dec 13, 2024InsiderOfficer sold ~$329K of SPRY shares in the open market
- Dec 17, 2024Insider · 2 peopleInsiders: 4 sales (~$2.3M)
- Jan 6, 2025InsiderDirector sold ~$555K of SPRY shares in the open market
- Feb 3, 2025InsiderDirector sold ~$616K of SPRY shares in the open market
- Mar 5, 2025InsiderDirector sold ~$4.4K of SPRY shares in the open market
- Mar 6, 2025InsiderDirector sold ~$556K of SPRY shares in the open market
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Ars Pharmaceuticals
For Ars Pharmaceuticals, OQRO holds 3 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its SPRY page.
Other recent filings by Flynn James E, 10% owner
- SEC Form 4 at Larimar Therapeutics (LRMR)Mar 3, 2026
- SEC Form 4 at Larimar Therapeutics (LRMR)Mar 3, 2026
- SEC Form 4 at Larimar Therapeutics (LRMR)Mar 3, 2026
- SEC Form 4 at Larimar Therapeutics (LRMR)Mar 3, 2026
- SEC Form 4 at Larimar Therapeutics (LRMR)Aug 4, 2025
The full history of Flynn James E, 10% owner is on the profile page.
How this filing works
Explore the data
Common questions
Which Ars Pharmaceuticals (SPRY) insider traded, and how much?
Flynn James E, 10% owner at Ars Pharmaceuticals, sold ~$708K of Ars Pharmaceuticals shares. 41K shares at $17.45.
When did it happen, and when was it made public?
Traded: Nov 11, 2024. Filed: Nov 14, 2024. That is 3 days between the two dates.
What stands out in this filing?
After this sale the filing reports 5,498,367 shares, held indirectly. 40,596 shares at an average of $17.45 each, as reported on the form. No footnote on the form refers to a pre-arranged trading plan (Rule 10b5-1).
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Ars Pharmaceuticals recently?
For Ars Pharmaceuticals, OQRO holds 3 insider filings (SEC Form 4 or Form 144) dated in the last 90 days. They are listed on the SPRY page.
Does this mean SPRY stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Ars Pharmaceuticals
- SEC Form 144Nov 9, 2026
- SEC Form 144Oct 30, 2026
- SEC Form 144Oct 19, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRMay 15, 2026
- SEC Form 13F-HRMay 15, 2026
Everything OQRO holds on this company is on its SPRY page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
